169 related articles for article (PubMed ID: 24002033)
1. MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth.
Sefton EC; Qiang W; Serna V; Kurita T; Wei JJ; Chakravarti D; Kim JJ
Endocrinology; 2013 Nov; 154(11):4046-57. PubMed ID: 24002033
[TBL] [Abstract][Full Text] [Related]
2. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.
Agarwal E; Chaudhuri A; Leiphrakpam PD; Haferbier KL; Brattain MG; Chowdhury S
BMC Cancer; 2014 Mar; 14():145. PubMed ID: 24581231
[TBL] [Abstract][Full Text] [Related]
3. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
4. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma.
Knowles JA; Golden B; Yan L; Carroll WR; Helman EE; Rosenthal EL
Laryngoscope; 2011 Nov; 121(11):2359-65. PubMed ID: 22020886
[TBL] [Abstract][Full Text] [Related]
7. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.
Cheng Y; Ren X; Zhang Y; Patel R; Sharma A; Wu H; Robertson GP; Yan L; Rubin E; Yang JM
Cancer Res; 2011 Apr; 71(7):2654-63. PubMed ID: 21307130
[TBL] [Abstract][Full Text] [Related]
8. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
Li Z; Yan S; Attayan N; Ramalingam S; Thiele CJ
Clin Cancer Res; 2012 Jul; 18(13):3603-15. PubMed ID: 22550167
[TBL] [Abstract][Full Text] [Related]
9. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.
Cheng Y; Zhang Y; Zhang L; Ren X; Huber-Keener KJ; Liu X; Zhou L; Liao J; Keihack H; Yan L; Rubin E; Yang JM
Mol Cancer Ther; 2012 Jan; 11(1):154-64. PubMed ID: 22057914
[TBL] [Abstract][Full Text] [Related]
10. Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth.
Lai WT; Cheng KL; Baruchello R; Rondanin R; Marchetti P; Simoni D; Lee RM; Guh JH; Hsu LC
Biochem Pharmacol; 2016 Aug; 113():12-23. PubMed ID: 27328368
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.
Somnay Y; Simon K; Harrison AD; Kunnimalaiyaan S; Chen H; Kunnimalaiyaan M
Anticancer Drugs; 2013 Jan; 24(1):66-72. PubMed ID: 23147412
[TBL] [Abstract][Full Text] [Related]
12. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.
Simioni C; Martelli AM; Cani A; Cetin-Atalay R; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2013 Sep; 4(9):1496-506. PubMed ID: 24036604
[TBL] [Abstract][Full Text] [Related]
13. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
[TBL] [Abstract][Full Text] [Related]
14. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of AKT induces cellular senescence in uterine leiomyoma.
Xu X; Lu Z; Qiang W; Vidimar V; Kong B; Kim JJ; Wei JJ
Endocrinology; 2014 Apr; 155(4):1510-9. PubMed ID: 24476133
[TBL] [Abstract][Full Text] [Related]
16. Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes.
Tan S; Ng Y; James DE
Biochem J; 2011 Apr; 435(2):539-44. PubMed ID: 21348862
[TBL] [Abstract][Full Text] [Related]
17. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
Malkomes P; Lunger I; Luetticke A; Oppermann E; Haetscher N; Serve H; Holzer K; Bechstein WO; Rieger MA
Ann Surg Oncol; 2016 Sep; 23(9):2849-57. PubMed ID: 27059026
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
[TBL] [Abstract][Full Text] [Related]
19. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells.
Jin R; Nakada M; Teng L; Furuta T; Sabit H; Hayashi Y; Demuth T; Hirao A; Sato H; Zhao G; Hamada J
Neurosci Lett; 2013 Feb; 534():316-21. PubMed ID: 23262078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]